Intellia Therapeutics Announces FDA Acceptance of BLA for Lonvo‑z

What Happened
Intellia Therapeutics (NTLA) filed an 8‑K on September 8, 2026 announcing that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo‑z, formerly NTLA‑2002) for hereditary angioedema (HAE) and granted Priority Review. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027 and has advised it is not currently planning to hold an advisory committee meeting. The company furnished a press release dated September 8, 2026 as Exhibit 99.1 to the 8‑K.

Key Details

• BLA acceptance and Priority Review announced on Sept 8, 2026; PDUFA (target action) date: March 10, 2027.
• FDA indicated it is not currently planning an advisory committee for this application.
• Lonvo‑z is Intellia’s in‑vivo CRISPR candidate for HAE (previously NTLA‑2002); if approved, it would be the first in‑vivo CRISPR‑based therapy and a one‑time treatment for HAE.
• The announcement was made via press release (Exhibit 99.1) and included standard forward‑looking statement disclosures.

Why It Matters
This is a major regulatory milestone: BLA acceptance and Priority Review create a clear regulatory timeline (PDUFA date) for investors to watch. Priority Review shortens the FDA review clock relative to standard review, and the absence of a planned advisory committee could mean a more straightforward review process. Approval would represent a potential first‑in‑class in‑vivo CRISPR therapy and a one‑time treatment option for HAE, which could have significant clinical and commercial implications. The filing also cautions that outcomes remain uncertain and points investors to Intellia’s existing filings (10‑K/10‑Q) for risk factors.